Hepatitis E virus: An underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation

Blood

Volumn 122, Issue 6, 2013, Pages 1079-1086

  Versluis, Jurjen ^a   Pas, Suzan D ^a   Agteresch, Hendrik J ^a,b   De Man, Robert A ^a   Maaskant, Jolanda ^a   Schipper, Marguerite E I ^a   Osterhaus, Albert D M E ^a   Cornelissen, Jan J ^a   Van Der Eijk, Annemiek A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Admiraal de Ruyter Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID; RIBAVIRIN; VIRUS RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CHRONIC HEPATITIS; CONCURRENT INFECTION; CROSS-SECTIONAL STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEPATITIS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; SEPSIS; SEROPREVALENCE; THROMBOCYTE TRANSFUSION; UMBILICAL CORD BLOOD; VIREMIA; VIRUS REACTIVATION; ADOLESCENT; ALLOTRANSPLANTATION; ENZYMOLOGY; EPIDEMIOLOGY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886914384     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-492363     Document Type: Article

References (26)

1. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet. 2012;379(9835):2477-2488.
2. Lewis HC, Wichmann O, Duizer E. Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiol Infect. 2010;138(2):145-166.
3. Dalton HR, Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8(11):698-709.
4. Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14(4):547-553.
5. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811-817.
6. Abravanel F, Mansuy JM, Huynh A, et al. Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. J Clin Virol. 2012;54(2):152-155.
7. le Coutre P, Meisel H, Hofmann J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58(5):699-702.
8. Koenecke C, Pischke S, Heim A, et al. Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country? Transpl Infect Dis. 2012;14(1):103-106.
9. Pfefferle S, Frickmann H, Gabriel M, et al. Fatal course of an autochthonous hepatitis E virus infection in a patient with leukemia in Germany. Infection. 2012;40(4):451-454.
10. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140(5):1481-1489.
11. Koning L, Pas SD, de Man RA, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. J Heart Lung Transplant. 2013;32(1):78-85.
12. Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis. 2011;17(1):30-37.
13. Pas SD, de Man RA, Mulders C, et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis. 2012;18(5):869-872.
14. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26(10):1429-1435.
15. Dalton HR, Stableforth W, Thurairajah P, et al. Autochthonous hepatitis E in southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2008;20(8):784-790.
16. Storek J, Espino G, Dawson MA, et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood. 2000;96(9):3290-3293.
17. Wils EJ, van der Holt B, Broers AE, et al. Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients. Haematologica. 2011;96(12):1846-1854.
18. Wils EJ, Cornelissen JJ. Thymopoiesis following allogeneic stem cell transplantation: new possibilities for improvement. Blood Rev. 2005;19(2):89-98.
19. Storek J, Gooley T, Witherspoon RP, et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol. 1997;54(2):131-138.
20. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)–specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101(11):4290-4297.
21. Broers AE, van der Holt B, Haze S, et al. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell–depleted peripheral blood progenitor cell transplantation versus T cell–depleted bone marrow transplantation. Exp Hematol. 2005;33(8):912-919.
22. Bouwknegt M, Lodder-Verschoor F, van der Poel WH, et al. Hepatitis E virus RNA in commercial porcine livers in The Netherlands. J Food Prot. 2007;70(12):2889-2895.
23. Baylis SA, Gärtner T, Nick S, et al. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang. 2012;103(1):89-90.
24. Beale MA, Tettmar K, Szypulska R, et al. Is there evidence of recent hepatitis E virus infection in English and north Welsh blood donors? Vox Sang. 2011;100(3):340-342.
25. Juhl D, Baylis SA, Blümel J, et al. Seroprevalence and incidence of hepatitis E virus infection in German blood donors [published online ahead of print February 26, 2013]. Transfusion.
26. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology. 2010;139(5):1612-1618.